Sionna Therapeutics has continued raising capital, closing a $182m Series C financing round to help advance additional cystic fibrosis candidates into clinical trials. The round, which was upsized ...
Hosted on MSN4mon
AbbVie invests in Sionna as part of licensing deal for CF drugsUnder the agreement, Boston, MA-based Sionna will obtain exclusive worldwide rights to develop and market AbbVie's CF-targeting clinical-stage assets galicaftor (ABBV-2222), navocaftor (ABBV-3067 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback